IP Library Granted Patent US 9,757,407
Granted Patent B2
US 9,757,407 · App. 14/977,424 · Granted Sep 12, 2017

Treatment of viral infections by modulation of host cell metabolic pathways

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,407
App. No.
14/977,424
Granted
Sep 12, 2017
Kind
B2
Abstract

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

Claims (1)

1. A method for treatment of cytomegalovirus infection in a human subject, comprising administering an effective amount of soraphen-A, or a pharmaceutically acceptable salt thereof to a human subject in need thereof.